Loading
Prescribing an approved drug for a use not listed on its official label, for example a different cancer or an earlier stage. Legal and common in oncology, but insurers may refuse to pay and the evidence is often thinner.
A drug's label (its licence) specifies the diseases, stages, biomarkers and prior treatments for which regulators have judged the evidence sufficient; anything else is off-label. In oncology perhaps a third of prescribing is off-label, driven by tumour-agnostic biology (a KRAS G12C inhibitor approved in lung cancer used in colorectal cancer), by rare cancers where trials are infeasible, and by guideline recommendations that run ahead of regulators. Compendia such as NCCN largely determine which off-label uses insurers will reimburse in the United States, and tumour-agnostic approvals and basket trials are ways of bringing rational off-label use onto the label.
Veterinary paste is dosed for animals by weight, and 'one squirt' is not a human dose. Liver injury of this severity can be fatal and this patient was fortunate to present in time.
The clearest documented case of what the label's neurotoxicity warning looks like in a cancer patient dosing herself.
This is the paper most often quoted online as proof. Patients reporting how they feel to the company that sold them the treatment, with 38 percent not answering, cannot show whether a cancer shrank, and the journal is now checking whether the underlying records exist.
The clearest recent statement of where the evidence stands: promising in a dish, untested in people, and already causing harm through self-dosing.
Shares Ivermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential?, Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort (with 2026 expression of concern), Fenbendazole (veterinary anthelmintic), Mebendazole.
Shares Fenbendazole (veterinary anthelmintic), Mebendazole, Ivermectin.
Shares Drug-induced liver injury following co-ingestion of veterinary fenbendazole and ivermectin for prostate cancer: a case report, Fenbendazole (veterinary anthelmintic), Ivermectin.
Shares ICONIC: ivermectin combined with immune checkpoint inhibition in cancer (University of Florida phase 2), Ivermectin.
Shares Rare cancers, Tumour-agnostic (tissue-agnostic) approval, Basket, umbrella, and platform trials.
Shares Mebendazole, Ivermectin.
Shares Mebendazole, Ivermectin.